Objective The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the
treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I …

Objective To assess over 3 years of follow-up the effects of maintaining or switching to
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …

Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …

Background and purpose Using the treatment goal of “no evidence of disease
activity”(NEDA) incorporating magnetic resonance imaging (MRI) re‐baselining, we aimed …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …

Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …